STAT3 the oncogene – still eluding therapy? by Wake, Matthew S & Watson, Christine
STAT3 the oncogene - Still eluding therapy? 
Matthew S Wake and Christine J Watson 
Department of Pathology, University of Cambridge, Tennis Court Road, 
Cambridge CB2 1QP, UK 
 
Abstract 
The STAT family of transcription factors transduce signals from cytokine receptors to 
the nucleus where STAT dimers bind to DNA and regulate transcription. STAT3 is 
the most ubiquitous of the STATs being activated by a wide variety of cytokines and 
growth factors. STAT3 has many roles in physiological processes such as 
inflammatory signalling, aerobic glycolysis, and immune suppression and was also 
the first family member shown to be aberrantly activated in a wide range of both solid 
and liquid tumours. STAT3 promotes tumourigenesis through regulating the 
expression of various target genes including cell cycle regulators, angiogenic factors 
and anti-apoptosis genes. Paradoxically, in some circumstances STAT3 signalling 
induces cell death. The best known example is the involuting mammary gland where 
STAT3 is essential for the induction of a lysosomal pathway of cell death. 
Nevertheless, direct silencing or inhibition of STAT3 diminishes tumour growth and 
cell survival in both animal and human studies. This suggests that abolishing STAT3 
activity could be an effective cancer therapeutic strategy. However, despite this 
potential as a therapeutic target and the extensive attempts by academia and 
pharmaceutical companies to develop an effective STAT3 inhibitor for use in the 
clinic, there has not been a single, direct STAT3 inhibitor approved for clinical use. In 
this review, we will focus on the role of STAT3 in tumourigenesis and discuss its 
potential as a therapeutic target for cancer treatment.  
 
Introduction 
The signal transducers and activators of transcription (STATs) are a family of seven 
proteins of close homology, STAT1, STAT2, STAT3, STAT4, STAT5a and closely 
related STAT5b, and STAT6. There are four known isoforms of human STAT3 
located on chromosome 17q21.31 (1). STAT3α, the predominantly expressed isoform, 
is a 770 amino acid, 88kDa protein that elicits most functions ascribed to STAT3 (2). 
STAT3β, an alternatively spliced variant, lacks the C-terminal domain and was 
described as a dominant negative form until evidence showed it to be a functional 
transcription factor (3). STAT3γ and STAT3δ, the lesser well known STAT3 
isoforms, may have roles in neutrophil and granulocytic differentiation respectively 
(4, 5). The structure of STAT3 is typical of the STAT family, comprising an N-
terminal domain, a coiled-coil domain, a Src homology 2 (SH2) domain, a DNA 
binding domain and a C-terminal transactivation domain (Figure 1) (6). The N-
terminal coiled-coiled domain forms an interface for dimer-dimer interactions during 
STAT3-driven initiation of gene expression (7, 8). The SH2 domain contains three 
important solvent accessible subpockets that stabilize STAT-STAT dimer interactions 
and STAT3-receptor binding interactions (9). The DNA-binding domain provides the 
protein-DNA binding interface, whereby upon activation, individual STAT monomers 
dimerize completing a nutcracker-like structure which binds to specific DNA motifs, 
initiating transcription (10). 
 
1. STAT3 activation  
STAT3 activation is mediated primarily by IL-6 family cytokine receptor-associated 
Janus kinases (JAKs) although receptor tyrosine kinases such as EGFR and non-
receptor tyrosine kinases such as Src can also phosphorylate STAT3 (Figure 2) (11-
13). Following JAK activation, latent cytosolic STAT3 monomers dock with 
cytokine-bound receptors at pTyr sites through SH2 domain binding, whereupon 
JAKs phosphorylate STAT3 on a conserved tyrosine residue (pTyr705) found in the 
C-terminal region. Post-phosphorylation, STAT3 monomers dissociate from receptor 
docking sites and dimerize through reciprocal pTyr and SH2 domain interactions (14). 
STAT3 is known to form homo and heterodimers with STAT1 due to the high 
sequence similarity between the two proteins, diversifying the number of genes under 
their transcriptional control (15). STAT3 can also be further modified by 
phosphorylation on a serine residue (S727) in the C-terminal region to promote full 
STAT3 activation. This serine residue, important in prolonging retention in the 
nucleus and affecting overall growth, is only present on the STAT3α isoform (16, 17). 
STAT3 can also be acetylated at Lys685 to alter expression of specific gene targets 
(18).  
 
2. STAT3 regulation 
STAT3 dimers regulate transcription of a variety of genes through binding to 
canonical palindromic CCT(N)3GAA sites in the promoter regions of target genes. 
Collectively, each STAT member elicits a wide range of important cellular responses 
and although DNA binding sites appear to be shared, each STAT displays specific 
gene expression signatures that seem to be cell type dependent (19). Expression and 
activation of STAT3 is exquisitely regulated in normal cells with a plethora of factors 
that silence JAK/STAT signalling. These include SOCS (suppressor of cytokine 
signalling) proteins that can bind to activated JAKs or receptor domains and 
efficiently block STAT phosphorylation. SOCS3 is a direct transcriptional target of 
STAT3, providing a cellular negative feedback mechanism for STAT3 signalling 
(20). The PIAS family (protein inhibitor of activated STAT) are a family of SUMO-
E3 ligases that covalently attach SUMO proteins to target substrates, thus altering 
their activity. PIAS3 in particular has been shown to directly inhibit STAT3 activity 
through this post translational modification (21). In addition to these, PTPs (protein 
tyrosine phosphatases), SHPs (Src homology domain-containing tyrosine 
phosphatases) and the more recently discovered PTPRT (protein tyrosine phosphatase 
receptor T) can specifically dephosphorylate STAT3 and upstream kinases in the 
JAK-STAT pathway to terminate STAT3 signalling (22).  
 
3. STAT3 as an oncogene 
STAT3 was first noted to be constitutively active in breast cancers (23). It became 
directly associated with oncogenic signalling when cells transformed by HTLV-1 and 
EBV viral infections were found to have constitutive STAT3 activity, a result of 
increased tyrosine kinase activity (24, 25). Furthermore, blocking STAT3 activity 
decreases cellular transformation in v-Src transformed cell lines (26). Further 
evidence that STAT3 is an oncogene was provided by expressing a mutated STAT3 
construct (STAT3C), that constitutively forms dimers, in normal mouse fibroblasts 
which, when transplanted into nude mice, formed tumours (27). This STAT3C 
construct was found to drive tumour formation in a variety of cell types by up-
regulating important oncogenic and angiogenic factors such as MMP-9, VEGF, and 
Cten (28-30).  
During tumourigenesis, STAT3 activity can become dysregulated, despite the 
impressive array of negative regulators of STAT3 signalling. Abnormal persistent 
STAT3 activity has been demonstrated in multiple haematological and solid cancers 
(31).  Of notable interest, constitutive STAT3 activity is found in a high percentage of 
triple negative breast cancers and in 30-60% of all primary breast cancers (32).  
Unlike most oncogenes, STAT3 mutations that contribute to aberrant STAT3 
signalling are not frequently found in tumours. A rare exception is the STAT3 SH2 
domain somatic mutations that were found in 12% of inflammatory hepatocellular 
adenomas that lacked mutations in the IL-6 receptor, which sensitized STAT3 
proteins to activation and homo-dimerization independently of IL-6 (33). In the 
majority of cases, however, persistent STAT3 activation occurs through deregulated 
upstream signalling where kinases that phosphorylate STAT3 can become over-
expressed or constitutively activated (32, 34). 
The primary distinction between STAT3 activation in normal and cancer cells is the 
level and duration of signalling. While cytokine-mediated activation of STAT3 is 
substantial and acute, oncogene-mediated STAT3 activation is generally at a lower 
level and prolonged (35). Some cancers become dependent upon, or addicted to this 
activity such that STAT3 inhibition restricts tumour growth and can induce cell death 
(36).  In addition to the tumour cells themselves, STAT3 activity in the tumour 
microenvironment plays a major role in tumour progression and metastasis. STAT3 
activation can induce expression of inflammatory cytokines such as IL-6 and 
angiogenic factors such as HIF1α and VEGF (30, 37). These inflammatory mediators 
promote wound healing but also influence cells in the tumour microenvironment via 
further induction of the JAK/STAT3 pathway (37, 38). Indeed, cancer has been 
considered as a wound that does not heal. The release of inflammatory and angiogenic 
factors driven by STAT3 in this microenvironment has suppressive effects on the 
immune system. Immature dendritic cells (DCs) are prevented from differentiating 
into antigen presenting cells, while macrophage expression of factors that promote 
Th1-mediated adaptive immune responses are suppressed (39, 40). Persistent STAT3 
activation in immature myeloid cells (iMCs) and naïve T-cells, promoted by STAT3 
induced cytokines, expands the populations of myeloid derived suppressor cells 
(MDSCs) and T regulatory (Treg) cells (41, 42). Treg cells directly inhibit CD4+ and 
CD8+ T cells through a cell-contact-dependent mechanism and induction of 
suppressive factors such as TGF-β and IL-10, aiding tumour immune evasion (42-44). 
Complete STAT3 ablation from the myeloid lineage leads to increased immune 
responses due to increased macrophage activation and production of Th1 cytokines 
(40). STAT3 ablation from the hematopoietic lineage produces a similar result with 
increases in activation of dendritic, natural killer and T-cells, resulting in suppressed 
tumour growth (42). 
 4. STAT3 as a viable therapeutic target: effects of inhibition on cancer 
growth 
As mentioned above, tumour cells are often highly susceptible to STAT3 inhibition or 
ablation (42, 45).  This is not surprising since STAT3 signalling promotes 
proliferation through the up regulation of cell cycle regulators such as cyclins D1, and 
D3 and c-Myc (45, 46). A variety of STAT3 inhibitors, including chemicals, decoy 
peptides and siRNA reagents have been developed, albeit often with limited efficacy 
(47, 48). STAT3 inhibition or siRNA knockdown has been shown repeatedly to 
increase cell death and reduce growth of tumours both in vivo and in vitro. For 
example, STAT3 inhibitor treatment of malignant glioma xenograft models 
suppressed the expression of c-Myc, Bcl-xL and Mcl-1, and induced apoptosis 
(49)while siRNA-mediated STAT3 inhibition in laryngeal tumours down regulated 
Bcl-2, survivin, and cyclin D1 protein levels and also induced apoptosis (50). In 
addition, STAT3 RNAi knockdown in aggressive breast cancer cell lines increased 
expression of apoptotic proteins Fas/Fas-L, while decreasing expression of anti-
apoptotic genes Bcl-xL and survivin, to induce apoptosis in vitro and in vivo (51). 
STAT3 is also implicated in epithelial-to-mesenchymal transition (EMT) which can 
contribute to invasion and metastasis. Transcription factors known to promote EMT, 
such as Twist and Snail are up regulated in cancers with aberrant STAT3 activity and 
STAT3 is required for TGF-β-induced EMT (52, 53). Consequently, STAT3 
inhibition reduces expression of these genes leading to reduced cancer cell invasion 
(53). Finally, persistent STAT3 signalling also directs cancer cells towards aerobic 
glycolysis, increasing proliferation and survival (54). Taken together, it is clear that 
STAT3 is implicated in multiple features of cancer cells highlighting the unmet need 
for effective inhibitors. 
In this context it is interesting to note that STAT3 inhibition in adult mice and recent 
human trials produced only moderate side effects in differentiated tissues suggesting 
that STAT3 drugs may not be highly toxic and encouraging the further development 
of STAT3 therapeutics (51, 55, 56). In addition, STAT3 inhibition sensitizes cancer 
cells to chemotherapeutic agents, highlighting the potential for STAT3 inhibitors in 
combinational cancer therapy (57, 58). However, STAT3 inhibitors need to be able to 
distinguish between STAT3 and STAT1 to be useful in a clinical setting. STAT3 and 
STAT1, although structurally very similar, display key differences in transcriptional 
targets. STAT1 provides an important anti-viral mechanism and is also a known 
tumour suppressor (59, 60). 
 
5. Strategies for inhibiting STAT3 signalling 
 
5.1 Indirect targets 
Most cases of persistent STAT3 activation are caused by activating mutations in, or 
overexpression of, upstream kinases such as JAK2, Src and EGFR.  A decrease in 
expression of STAT3 negative regulators such as SOCS and PIAS, as observed in 
hepatocellular carcinoma and mesothelioma tumours respectively, can also result in 
constitutive STAT3 activity (61, 62). Several drugs that can target these components 
are already in clinical trials or in use in the clinic, including the JAK2 inhibitor 
Ruxolitinib and the EGFR blocking antibody Cetuximab (63, 64). Furthermore, key 
methyltransferases and acetyltransferases specific to STAT3 could also be targeted as 
additional therapeutic options for STAT3 inhibition (65, 66).  
 
Overexpression of EGFR can contribute to aberrant STAT3 activity and is abundant 
in squamous cell carcinoma of the head and neck (SCCHN), a leading cause of death 
worldwide (67). EGFR is also overexpressed in approximately 16-36% of all breast 
carcinomas and may harbour activating mutations (68).  
 
Aberrant STAT3 activity in cancer is also frequently caused by overactive members 
of the JAK family (32, 34). A breakthrough in understanding myeloproliferative 
diseases occurred after discovering JAK2 activating mutations leading to a novel class 
of oral JAK2 inhibitors (69). As such, many FDA-approved JAK kinase specific 
inhibitors are now in clinical use for cancer treatment. Ruxolitinib, the first FDA-
approved JAK1 and JAK2 specific kinase inhibitor for myeloproliferative disease 
treatment, is now prescribed for other types of cancer with constitutive STAT3 
activity, such as lymphomas and pancreatic cancer (70, 71). STAT3 activity is 
inhibited by Ruxolitinib, inducing apoptosis and reducing cisplatin resistance in non-
small-cell lung cancer (NSCLC) cell lines  (72). AZD1480, another FDA-approved 
JAK2 inhibitor for myeloproliferative disease treatment, also displays significant 
pSTAT3 reduction in solid tumours, reducing growth of many cell lines with 
constitutive STAT3 activity (73). Furthermore, JAK2 specific inhibitors such as 
Pancritinib are in the final stages of clinical trials for myelofibrosis and display 
increased potency compared to currently available JAK inhibitors (74).  
 
5.2 Directly inhibiting STAT3  
Despite persistent attempts by many laboratories and pharmaceutical companies to 
develop STAT3 inhibitors, this has yet to be satisfactorily achieved raising the 
question of whether STAT3 is truly a druggable target. Many direct STAT3 inhibitors 
have been identified or produced using a variety of techniques, including screens of 
large compound libraries, computer assisted virtual screening with the STAT3 crystal 
structure, optimization of natural STAT3 inhibitor compounds and STAT3- binding 
peptides, and fragment-based drug design and drug repositioning using multiple 
ligand simultaneous docking (MLSD) (75-77). These inhibitors can be placed into 
three broad groups; peptides, small molecules and oligonucleotides. All groups act on 
STAT3 through targeting one of three STAT3 motifs namely the N-terminal domain, 
the SH2 domain and the DNA binding domain (DBD) (Figure 3). Peptide inhibitors 
mimic STAT3 binding protein sequences to interrupt protein-protein interactions and 
can be directed towards all three sites. SH2 domain peptide inhibitors, for example, 
are based on the SH2 domain binding motif pTyr-Xxx-Xxx-Gln (where Xxx 
represents any amino acid) (47, 78). The majority of small molecule inhibitors are 
claimed to bind the STAT3 SH2 domain although some are directed towards the DBD 
(79-81). In contrast oligonucleotide decoy inhibitors, that resemble the STAT3 DNA 
binding site in the c-fos promoter, act solely on the STAT3 DBD to prevent DNA 
binding and transcriptional activation (55). 
 
Thus, there are a number of STAT3 domains that are potentially targetable by 
therapeutics and these will be discussed in more detail below. 
 
6. Targetable STAT3 Domains 
 
6.1 The N-terminal domain  
The N-terminal coiled-coil domain interface is formed of 4 helices that are grouped to 
form a hook-like structure and is responsible for protein-protein interactions and 
formation of multiple oligomers (82). Here, two STAT3 DNA-bound dimers interact 
to form a transcription initiating tetramer (7, 8). In addition this region is required for 
successful nuclear shuttling of phosphorylated and unphosphorlyated STAT3 
monomers (83). ST3-H2A2, a synthetic peptide discovered from a library directed 
towards STAT3 N-Domain binding, successfully binds at this site to specifically 
inhibit STAT3 function but not that of STAT1. The N-Domain of STAT1 displays 
considerable differences in sequence to STAT3, and therefore is not recognised by the 
tailored peptide. ST3-H2A2 modified regulation of STAT3 gene targets, increasing 
expression of 17 pro-apoptotic genes and inducing apoptosis (84). Furthermore, ST3-
H2A2 could be made more membrane permeable by tagging the C-terminus to 
Penetratin, a 16 amino acid peptide internalized by cells (85).  
 
6.2 The SH2 domain 
The STAT3 SH2 domain is a 100 amino acid sequence containing three solvent-
available subpockets that can interact with activated receptors and a second STAT3 
monomer (9, 82). These pockets interact with key sites, the pTyr-705, the adjacent 
leucine residue and additional hydrophobic residues on a second STAT3 monomer to 
stabilize STAT3 dimer interactions. STAT3 SH2 domain inhibitors prevent docking 
with receptors and dimerization, thereby blocking activation and function (9). Many 
SH2 domain-binding peptides have been synthesized with high potency, some with 
IC50 values in the low nanomolar range (78). For example, PY
*
LKTK-mts and 
APTSTAT3-9R potently inhibit STAT3 activation and dimerization, inhibiting tumour 
cell growth and inducing apoptosis in vitro and in vivo (47). STA-21, a small 
molecule discovered from a virtual screen of over 400,000 compounds against the 
STAT3 SH2 domain, inhibits STAT3 activity and DNA binding at 20 µM and has 
completed phase II clinical trials as a topical agent for STAT3 driven psoriasis (75, 
86). LLL-12, an optimized analogue of STA-21, blocked STAT3 activation and DNA 
binding at 2 µM, suppressing tumour growth and inducing apoptosis (87).  Stattic, 
another small molecule STAT3 SH2 domain inhibitor, was discovered in a fluorescent 
polarization (FP) compound screen against the STAT3 SH2 domain and inhibits 
STAT3 DNA binding at 10 µM with specificity over STAT1 (79). BP-1-102, a 
structurally modified analogue of S31-201, displays binding to all three subpockets of 
the STAT3 SH2 domain and inhibits STAT3 activity at 20 µM, reducing growth and 
invasion of multiple tumour cell line xenografts (9). Inhibitors claiming to inhibit the 
STAT3 SH2 domain are the most numerous of all STAT3 inhibitors with many other 
notable examples (88). 
 
6.3 DNA binding domain 
The STAT3 DNA-binding domain (DBD) is constituted of four loops originating 
from the DBDs and linker domains from each STAT3 monomer (82). Inhibitors 
binding here impede STAT3 binding to target DNA sequences and thus gene 
expression. Peptide inhibitors directed towards the STAT3 DBD, discovered through 
yeast two hybrid display of STAT3 DBD, inhibited STAT3 transcriptional activity 
with high potency, inhibiting growth and inducing apoptosis of human myeloma cells 
(89). InS3-54, a small molecule STAT3 DBD inhibitor discovered through a virtual 
screen against the crystal structure of STAT3β-complexed to DNA, also inhibited 
STAT3 transcriptional activity in a time and dose dependent manner (90). Decoy 
oligonucleotides, closely resembling STAT3 DNA binding sites, bind STAT3 dimers 
and prevent nuclear localisation and DNA binding. One such example induced 
apoptosis and growth inhibition in many cancerous cell lines with constitutive STAT3 
activity but did not affect normal cells (55). In a recent phase 0 trial this STAT3 decoy 
oligonucleotide proved to have tolerable toxicology and promising efficacy in 
xenograft models and in humans, inhibiting STAT3 gene targets in patients with 
HNSCC and reducing the tumour growth (55). 
 
7. Why have STAT3 inhibitors not reached the clinic? 
Despite these achievements the question remains as to why no STAT3 inhibitors have 
reached the clinic. Peptide therapeutics, although specific and highly potent, suffer 
from rapid degradation and instability, although considerable progress has been made 
into improving peptide pharmacokinetic and pharmacodynamic profiles (91). SH2 
domain binding peptidomimetics also require phosphorylated tyrosine residues to bind 
to the STAT3 SH2 domain, an essential negative charge that limits cell membrane 
penetrance, drastically reducing efficacies in vitro and in vivo (47).  Poor membrane 
permeability can also be improved however, by the addition of membrane 
translocating sequences or further modification (47, 85). Modified STAT3 specific 
peptides may yet provide a viable option for targeting STAT3 in vivo, although as yet, 
the aforementioned limitations has meant that none have moved into clinical trials. In 
contrast, small molecules efficiently cross the membrane. However, FDA-approved 
small molecule inhibitors are dominated by kinase inhibitors that mimic the structure 
of ATP and bind the deep hydrophobic ATP binding cleft, a site that STAT3 lacks. 
The three inhibitory sites mentioned above are large, planar surfaces that prove 
difficult for small molecules to bind to specifically and block the large protein-protein 
interactions. Many small molecule "STAT3 inhibitors",  identified from virtual and 
high-through-put screens, displayed unsaturated ketone groups that can be responsible 
for forming non-specific bonds with nucleophilic groups of peptides (92). The binding 
affinity of Stattic to STAT3, for example, was dramatically reduced in the presence of 
2 mM DTT, a strong nucleophile, suggesting electron donation saturates the 
electrophilic group of Stattic and prevents effective STAT3 binding. Furthermore, 
inhibition was reduced when a nitro group of Stattic, a strong electron acceptor, was 
replaced with NH2 or H (79). This raises the question; are STAT3 specific inhibitors 
binding specifically or adhering to protein surfaces non-specifically? The majority of 
STAT3 SH2 domain small molecule inhibitors are lacking crucial evidence of specific 
STAT3 binding. Despite this caveat, there are a number of small molecule STAT3 
inhibitors currently undergoing clinical trials, such as STA-21 for the treatment of 
psoriasis.  OPB-31121 and OPB-51602 have also completed phase I trials for the 
treatment of advanced cancer (93, 94). DNA oligonucleotide therapeutics suffer poor 
bioavailability, poor pharmacokinetics and short half-lives in vivo due to rapid 
nuclease degradation, which has meant very few have reached the clinic (95). The 
half-life of the unmodified STAT3 decoy oligonucleotide was short but could be 
extended following 5’ and 3’ end modification to create a cyclic molecule, inhibiting 
degradation (55). Other oligonucleotide therapeutics have been modified at the 
phosphate backbone to increase stability and reduce degradation in vivo (95). 
Membrane permeability and tissue specific delivery have remained problematic for all 
oligonucleotide therapies however, and has thus limited clinical use (96). 
 
8. STAT3 therapeutics: future perspectives 
Evidence continues to accumulate that STAT3 is an oncogene and an important target 
for therapy. Recent analysis of the six main breast cancer subtypes, basal-like, luminal 
A, luminal B, ERBB2/HER2+, normal breast-like and claudin low, suggests 
constitutive STAT3 activity is predominantly associated with basal-like breast cancers 
(97). This important finding re-establishes STAT3 as a desirable therapeutic target, as 
basal-like breast cancer often lacks the three treatable breast cancer markers, estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) (98). However, despite intensive efforts, STAT3 has remained 
frustratingly elusive as a target for cancer therapy. There are a large number of 
STAT3 inhibitors currently undergoing clinical trials, which shows that with 
technological advances and the continuous improvement to all approaches, progress is 
being made. However, the lack of a clinically applicable STAT3 inhibitor has brought 
to light the problems still being encountered. Lack of cell penetrance, lack of binding 
specificity and rapid degradation are some examples of the problems that have needed 
to be addressed. Most inhibitors and methods of delivery described in this review will 
require more research and development if they are to become the next generation of 
cancer therapies. A non-specific compound is likely to cause off target effects 
resulting in cytotoxicity and a likely failure in clinical trials. Whereas a molecule that 
is too rapidly degraded in vivo, or that lacks membrane permeability will undoubtedly 
lack efficacy in a clinical setting. Nevertheless, providing clinicians with an addition 
to the armamentarium in the fight against therapy-resistant cancer will always justify 
the resources and effort required to develop a STAT3 specific therapeutic.  
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Figure legends 
 
Figure 1. A linear diagram depicting functional STAT3 domainsN-Domain, coiled-
coil domain, DNA binding domain, linker domain, SH2 domain and transactivation 
domain are all presented with amino acid numbers indicating boundaries between 
each. Phosphorylation sites Tyr705 and Ser727 and acetylation site Lys685 are also 
displayed. 
 
Figure 2. The activation and regulation of the STAT3 pathway. Binding of 
stimulatory ligands to cell surface receptors induces members of the JAK family to 
cross-phosphorylate each other and then specific domains on the cytokine receptors. 
This provides binding sites for the recruitment and phosphorylation of STAT3 
monomers. STAT3 can be activated also by receptor and non-receptor tyrosine 
kinases such as EGFR and Src respectively. Phosphorylated STAT3 monomers 
homodimerize and translocate to the nucleus where they bind DNA and regulate 
transcription of target genes. STAT3 signalling is regulated via many negative 
feedback controls. SOCS members, some of which are directly upregulated by 
STAT3, bind either to JAKs or to receptor-binding sites where they compete with 
STAT3. PIAS members lead to direct degradation of STAT3 protein while 
phosphatases, such as PTP and SHP-1, lead to dephosphoryation of kinases and 
STAT3 to inhibit signalling.  
 
 
Figure 3. Schematic diagram of the DNA bound STAT3β homodimer complex and 
potential binding sites for inhibitor compounds on the STAT3β monomer. The 
STAT3-DNA complex (PDB code 1BG1) with the N-terminal oligomerization 
domain depicted in green, DNA binding domain in orange, linker domain in blue, 
SH2 domain in red and C-terminal phosphotyrosine containing region in grey.  A. A 
solid surface view of entire complex viewed from along the DNA axis. B. Ribbon 
surface STAT3β-DNA complex close up view along DNA axis. C. Solid surface view 
of STAT3β monomer and potential inhibitor binding sites with examples. This figure 
was designed using the program Chimera. Inhibitor compounds are referenced in the 
text.  
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